Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Kyowa Kirin) of mogamulizumab (Poteligeo(®)), as part of the single technology appraisal process, to submit evidence for its clinical and cost-effectiveness for previously treated mycosis fungoides (MF) and Sézary...

Descripción completa

Detalles Bibliográficos
Autores principales: Grimm, Sabine E., Witlox, Willem, Wolff, Robert, Chalker, Annette, Hiligsmann, Mickael, Wijnen, Ben, Ahmadu, Charlotte, Ryder, Steve, Armstrong, Nigel, Duffy, Steven, Syndikus, Isabel, Kleijnen, Jos, Joore, Manuela A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095533/
https://www.ncbi.nlm.nih.gov/pubmed/34664200
http://dx.doi.org/10.1007/s40273-021-01098-3

Ejemplares similares

Ejemplares similares